KALV241220C2500
- 0.00
- 0.000.00%
KalVista Pharmaceuticals Newsroom
Needham Maintains KalVista Pharmaceuticals(KALV.US) With Buy Rating, Cuts Target Price to $28
KalVista Pharmaceuticals: Strategic Financing and Market Potential Drive Buy Rating
KalVista Pharma Analyst Ratings
H.C. Wainwright Maintains KalVista Pharmaceuticals(KALV.US) With Buy Rating, Maintains Target Price $20
KalVista Pharmaceuticals Initiated at Buy by Jones Trading
KalVista Pharma Analyst Ratings
JonesTrading Initiates KalVista Pharmaceuticals(KALV.US) With Buy Rating, Announces Target Price $35
Buy Rating Affirmed for KalVista Pharmaceuticals Amid Strong Phase 3 Data and Market Potential
Leerink Partners Maintains KalVista Pharmaceuticals(KALV.US) With Buy Rating, Maintains Target Price $20
H.C. Wainwright Maintains KalVista Pharmaceuticals(KALV.US) With Buy Rating, Maintains Target Price $20
KalVista Pharma Analyst Ratings
Needham Maintains KalVista Pharmaceuticals(KALV.US) With Buy Rating, Maintains Target Price $32
Buy Rating for KalVista Pharmaceuticals Amid Positive Regulatory Developments and Strong Financial Position
Stifel Maintains KalVista Pharmaceuticals(KALV.US) With Buy Rating, Maintains Target Price $39
Analysts' Top Healthcare Picks: KalVista Pharmaceuticals (KALV), RegenXBio (RGNX)
Analysts' Opinions Are Mixed on These Healthcare Stocks: KalVista Pharmaceuticals (KALV), Roche Holding AG (OtherRHHVF) and Pfizer (PFE)
HC Wainwright & Co. Reiterates Buy on KalVista Pharma, Maintains $20 Price Target
Buy Rating on KalVista Pharmaceuticals: Sebetralstat Poised to Transform HAE Treatment Landscape
Needham Adjusts Price Target on KalVista Pharmaceuticals to $32 From $35, Maintains Buy Rating
Jefferies Issues a Buy Rating on KalVista Pharmaceuticals (KALV)